Source: Eur Respir Rev 2013; 22: 148-152
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Toby M. Maher. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013; 22: 148-152

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 Idiopathic pulmonary fibrosis: classification, epidemiology, course and prognosis Source: International Congress 2016 – Russia Session Year: 2016 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features Source: Eur Respir J 2006; 27: 143-150 Year: 2006 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016